Differences in the metabolism and pharmacokinetics of two structurally similar PPAR agonists in dogs: Involvement of taurine conjugation

Xenobiotica

Volumn 34, Issue 7, 2004, Pages 665-674

  Kim, M S ^a   Shen, Z ^a   Kochansky, C ^a   Lynn, K ^a   Wang, S ^a   Wang, Z ^a   Hora, D ^a   Brunner, J ^a   Franklin, R B ^a   Vincent, S H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 [2 CHLORO 4 (2,2,2 TRIFLUOROETHOXY)PHENOXY]PROPOXY] 3,4 DIHYDRO 2 METHYL 2H BENZOPYRAN 2 CARBOXYLIC ACID; 7 [3 [2 CHLORO 4 (4 FLUOROPHENOXY)PHENOXY]PROPOXY] 2 ETHYL 3,4 DIHYDRO 2H BENZOPYRAN 2 CARBOXYLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TAURINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILE; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; RADIOACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; BENZOPYRANS; BILE; DOGS; HALF-LIFE; MALE; METABOLIC CLEARANCE RATE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TAURINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 4143138498     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250412331285445     Document Type: Article

References (21)

1. BERGER, J. and MOLLER, D., 2002, The mechanisms of action of PPARs. Annual Review of Medicine, 53, 409-435.
2. CALDWELL, J., 1982, Metabolism of functional groups. In W. B. Jakoby, J. R. Bend and J. Caldwell (eds), Metabolic Basis of Detoxication (New York: Academic Press), pp. 271-290.
3. CALDWELL, J., EMUDIANUGHE, T. S. and SMITH, R. L., 1979, Species variation in the taurine conjugation of clofibric acid. British Journal of Pharmacology, 66, 421P-422P.
4. DESVERGENE, B. and WAHLI, W., 1999, Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrinology Review, 20, 649-688.
5. DIXON, P. A., CALDWELL, J. and SMITH, R. L., 1977, Metabolism of arylacetic acids. The fate of 1-naphthylacetic acid and its variation with species and dose. Xenobiotica, 7, 695-706.
6. EMUDIANUGHE, T. S., CALDWELL, J., SINCLAIR, K. A. and SMITH, R. L., 1983, Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man. Drug Metabolism and Disposition, 11, 97-102.
7. EMUDIANUGHE, T. S., CALDWELL, J. and SMITH, R. L., 1987, Comparative metabolic conjugation of 1- and 2-naphthylacetic acids in the guinea pig, mouse, hamster and gerbil. Xenobiotica, 17, 15-21.
8. EZZET, F., KRISHNA, G., WEXLER, D. B., STATKEVICH, P., KOSOGLOU, T. and BATRA, V. K., 2001, A population phamacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clinical Therapeutics, 23, 871-885.
9. HUTT, A. J. and CALDWELL, J., 1990, Amino acid conjugation. In G. J. Mulder (ed.), Conjugation Reactions in Drug Metabolism (London: Taylor & Francis), pp. 273-305.
10. KERSTEN, S, DESVERGENE, B. and WAHLI, W., 2000, Roles of PPARs in health and disease. Nature, 405, 421-423.
11. KILLENBERG, P. G. and WEBSTER, L. T., 1980, In W. B. Jakoby (ed.), Enzymatic Basis of Detoxication II (New York: Academic Press), pp. 141-167.
12. KOYAMA, H., MILLER, D. J., BOUERES, J. K., DESAI, R. C., JONES, A. B., BERGER, J. P., MACNAUL, K. L., KELLY, L. J., DOEBBER, T. W., WU, M. S., ZHOU, G., WANG, P.-R., IPPOLITO, M. C., CHAO, Y.-S., AGRAWAL, A. K., FRANKLIN, R., HECK, J. V., WRIGHT, S. D., MOLLER, D. E. and SAHOO, S. P., 2004, (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents. Journal of Medicinal Chemistry, 47, 3255-3263.
13. LEVY, G. and GIACOMINI, K. M., 1978, Rational aspirin dosage regimens. Clinical Pharmacology and Therapeutics, 23, 247-252.
14. LEVY, G., 1965a, Salicylurate formation - demonstration of Michaelis-Menten kinetics in man. Journal of Pharmaceutical Sciences, 54, 96.
15. LEVY, G., 1965b, Pharmacokinetics of salicylate elimination in man. Journal of Pharmaceutical Sciences, 54, 959-967.
16. LEVY, G., TSUCHIYA, T. and AMSEL, L. P., 1972, Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clinical Pharmacology and Therapeutics, 13, 258-268.
17. OUELLET, D. M. C. and POLLACK, G. M., 1995 Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Drug Metabolism and Disposition, 23, 487-494.
18. PATRICK, J. E., KOSOGLOU, T., STAUBER, K. L., ALTON, K. B., MAXWELL, S. E., ZHU, Y. L., STATKEVICH, P., IANNUCCI, R., CHOWDHURY, S., AFFRIME, M. and CAYEN, M. N., 2002, Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metabolism and Disposition, 30, 430-437.
19. ROBERTS, M. S., MAGNUSSON, B. M., BURCZYNSKI, F. J. and WEISS, M., 2002, Enterohepatic circulation - physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics, 41, 751-790.
20. SCHOONJANS, K., STAELA, B. and AUWERX, J., 1996, The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochimica et Biophysica Acta, 1302, 93-109.
21. WAHLI, W., BRAISSANT, O. and DESVERGNE, B., 1995, Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chemistry and Biology, 2, 261-266.